Wedbush analyst Laura Chico lowered the firm’s price target on Biogen (BIIB) to $135 from $166 and keeps a Neutral rating on the shares. The firm notes the primary focus for the Q4 update centered on the forward outlook and FY25 guidance targets. Wedbush believes it remains challenging to identify tangible growth drivers. Relative to large-cap peers, Biogen’s revenue growth rate remains below average.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $200 from $275 at TD Cowen
- Biogen price target lowered to $157 from $192 at Morgan Stanley
- Biogen (BIIB) Q4 Results Make Analysts Feel Poorly About its Prospects
- Biogen price target lowered to $241 from $300 at H.C. Wainwright
- Cautious Outlook on Biogen Amid Declining MS Revenues and Uncertain Growth Prospects
Questions or Comments about the article? Write to editor@tipranks.com